We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Fevertree Drinks Plc | FEVR | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 12.00 | 1.73% | 705.50 | 16:35:09 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 713.50 | 695.00 | 715.00 | 705.50 | 693.50 |
| Industry Sector |
|---|
| BEVERAGES |
| Top Posts |
|---|
Posted at 30/1/2025 16:50 by edwardt if i am being honest - it strikes me UK invstors have no balls. if the US was such a great opportunity -investors should have been willing to fund it. Now it is less capital light and de risked - they want to own the stock. I will hold mine as we will bounce to sensible levels but the true blue sky valuation has gone to the yanks |
Posted at 30/1/2025 15:30 by grabster "the Coors Light-to-Carling brewer will take over Fevertree’s US operations, while Fevertree will receive a share of the profits of the US operations as a royalty, which should materially improve over time. Historically, Fevertree’s growth in the US has required significant working capital investment, but this cost will now all be on Molson Coors’ books."investors An hour after US market opened, shares in Molson Coors (NYSE:TAP) are up around 1% on news of the deal - which maybe suggests the market regards FEVR as being the far bigger beneficiary. |
Posted at 09/1/2025 19:37 by wetdream From today’s Times:Re Diageo ‘The veteran investor Terry Smith offloaded his fund’s stake in the owner of Guinness and Johnnie Walker whisky over concerns that the development of anti-obesity drugs could reduce demand for alcohol.’ |
Posted at 27/9/2024 20:29 by philanderer Questor tipLike Terry Smith, we’re keeping hold of this underperformer Investors need to be patient but Fever-Tree’s strategy will come good |
Posted at 06/9/2024 15:00 by martywidget Evening all...Next week: Fevertree, Half Year Results, Thursday 12 September Aarin Chiekrie, equity analyst, Hargreaves Lansdown: Last investors heard, Fevertree LON:FEVR had been scooping up market share across its regions which had helped to increase sales. Innovation across Rum, Vodka and other spirits has helped boost the group’s leading position in the UK, and growth in Europe continues to grow ahead of the broader mixer category. Fevertree’s already said it’s comfortable with full-year expectations, which at the time of the last update in June pointed towards 8% sales growth and underlying cash profit margins of around 15%. Markets will be keeping a close eye on whether these targets are still on track when half-year results are announced next week, with market forecasts currently suggesting this could be a slight stretch. |
Posted at 01/5/2024 17:47 by whittler100 It’s an interesting stock with a pedigree history & has some heavy-weight investors; Fundsmith 7.6% & Lindsell Train 15%. Just my opinion but reasonable mileage to come over the next couple of years.The Deutsche Bank “Buy” of 30/04/24 was an interesting read. |
Posted at 26/3/2024 11:56 by edwardt i guess with the US 12x to the UK market - investors are focused on the TAM there. |
Posted at 04/2/2024 21:24 by apad Based on the long-term graph £10 looks like a base.It doesn't really matter if you are a long-term investor. It is all about maintaining brand value, which doesn't show on the balance sheet. Pears Soap is a wonderfull case study about what happens if you don't work hard at promoting the brand. apad |
Posted at 16/1/2024 14:14 by philanderer Liberum upgrades Fevertree on recovery prospectsLiberum has upgraded premium mixer maker Fevertree (FEVR) as a trough in margins indicates a recovery in this year and next. Analyst Anubhav Malhotra upgraded his recommendation from ‘hold’ to ‘buy’ and increased the target price from £12.00 to £13.00 on the stock, which was trading at £9.98 on Monday. Malhotra said the company’s strategy ‘has been focused on market share gains against a backdrop of significant input cost inflation over the last two years’. Margins have ‘troughed̵ ‘We see scope for a greater recovery in 2024 and 2025 than consensus expects and therefore move to ‘buy’ ‘Despite the [fact] that ‘bad news’ might not be over, the valuation at 17x 12 months forward consensus embedded value/Ebitda and 28x price/earnings – 40-50% below historic average – looks reasonable.’ Mahotra said that for investors ‘wanting to build a position, now is the time considering the low average daily volume of 265,000’. citywire.com |
Posted at 25/1/2023 15:28 by martywidget 26th January 2023 - FY22 Pre-close trading updateMarch 2023 FY22 - Preliminary Results |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
